TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02862600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of bioanalytical assay to monitor plasma levels of perhexiline
Description: The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
Study: NCT01010217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycofenolate mofetil
Description: 15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
Study: NCT04418583

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging
Description: Three-dimensional surface images, acquired by the Artec Leo
Study: NCT03827148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care
Description: Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
Study: NCT01010217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycofenolate mofetil
Description: 15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycofenolate mofetil
Description: 15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
Study: NCT01439711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT05212493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis oil
Description: Cannabis oil 20:1 CBD:THC ratio

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis oil
Description: Cannabis oil 20:1 CBD:THC ratio
Study: NCT03428750

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN3835
Description: Collagenase clostridium histolyticum

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04184024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Soft tissue massage known as Swedish massage technique was applied to the neck area for 20 minutes. This massage was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape
Description: Patients were taped according to the Kenzo Kase's Kinesio Taping Method by an experienced physical therapist. The application was carried out in a relaxed sitting position. Y banding with extensor muscles on the back of the neck with muscle technique, I banding with the upper trapezius with muscle technique and I banding with ligament technique to the middle region of the neck were performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stabilization exercise
Description: Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stabilization exercise
Description: Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
Study: NCT03295006

Intervention type: DEVICE
Intervention: TheraSphere
Description: Patients who had received TheraSphere
Study: NCT03550729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).
Study: NCT04590326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5668
Description: REGN5668 will be administered by once weekly intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5668
Description: REGN5668 will be administered by once weekly intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: For Module 1, after a minimum of a 3-week monotherapy lead-in of REGN5668, cemiplimab will be administered concomitantly every 3 weeks (Q3W) by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4018
Description: For Module 2, a 4-5 week monotherapy lead-in of REGN4018 will be administered by once weekly IV infusion. After lead-in, REGN5668 and REGN4018 will be administered concomitantly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Administered by IV infusion as prophylaxis for mitigating potential CRS in patients receiving REGN4018
Study: NCT01531140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol +Bisacodyl
Description: Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Polyethylene glycol p.o.: 60 ml/kg/days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sennosides
Description: Sennosides 1tbl/8kg for 2 days
Study: NCT01699893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unique arm
Description: blood, nasal swab, skin biopsy, stool samples
Study: NCT02153294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low tidal volume
Description: Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: high tidal volume
Description: Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
Study: NCT05463627

Intervention type: DRUG
Intervention: Metformin
Description: All participants among the three groups were treated with metformin

Intervention type: DRUG
Intervention: Metformin
Description: All participants among the three groups were treated with metformin
Study: NCT01780493

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The Direct Nipple Ureteroneocystostomy Technique
Study: NCT01121640

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CA125 assay on Abbott Architect i1000SR platform
Description: Bead-based sandwich ELISA style assay

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CA125 assay on Abbott Architect i1000SR platform
Description: Bead-based sandwich ELISA style assay
Study: NCT03838848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 3mg/kg, Q2W, intravenous injection (IV)
Study: NCT01121640

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HE4 assay on Architect i1000SR platform
Description: Bead-based sandwich ELISA style assay

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HE4 assay on Architect i1000SR platform
Description: Bead-based sandwich ELISA style assay

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvaginal Ultrasound
Description: Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvaginal Ultrasound
Description: Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
Study: NCT01474408

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interval training day 1
Study: NCT03838848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 5mg/kg, Q2W, intravenous injection (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 5mg/kg, Q2W, intravenous injection (IV)
Study: NCT01474408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interval training day 1

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interval training day 1

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate exercise day 2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate exercise day 2

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate exercise day 2

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control day 3

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control day 3

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control day 3
Study: NCT03838848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 5mg/kg, Q2W, intravenous injection (IV)
Study: NCT02509351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placeboo
Description: women will recive 2 identical tablets as placeboo
Study: NCT03141528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-learning
Description: Training without supervision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructor-led learning
Description: Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
Study: NCT00669747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin i.d. Days 1 & 15
Description: Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin i.d. Day 1; Normal Saline i.d. Day 15
Description: Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline, 10 ml, i.d. on Days 1 and 15
Study: NCT04280926

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Troponin Testing
Description: Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
Study: NCT03838848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 5mg/kg, Q3W, intravenous injection (IV)
Study: NCT04436107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg administered orally twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg administered orally twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered as specified in the treatment arm
Study: NCT04543591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Study: NCT04006717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser therapy
Description: Diode laser (EPIC™ BIOLASE) with wavelength 940nm

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level Laser therapy
Description: Diode laser (EPIC™ BIOLASE) with wavelength 940nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser therapy
Description: Diode laser (EPIC™ BIOLASE) with wavelength 940nm
Study: NCT05463627

Intervention type: DRUG
Intervention: Metformin
Description: All participants among the three groups were treated with metformin
Study: NCT00453388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT03954938

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Craving Manipulation
Description: Craving will be manipulated based on instructions about cocaine associated images shown to subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving Manipulation
Description: Craving will be manipulated based on instructions about cocaine associated images shown to subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
Study: NCT03382860

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus videos
Description: Recordings of fundus videos

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus videos
Description: Recordings of fundus videos
Study: NCT02542579

Intervention type: GENETIC
Intervention: 16S rRNA pyrosequencing analysis
Description: Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
Study: NCT03390400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecondlaser-assisted
Description: Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecondlaser-assisted
Description: Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Capsulotomy
Description: Cataract Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lens Fragmentation
Description: Cataract Surgery
Study: NCT02531711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet A
Description: Experimental analgesic dietary intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: Healthy comparator diet
Study: NCT01862965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PredEver
Description: Firstline treatment with prednisone and Everolimus
Study: NCT03990337

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasonography of cricoid cartilage.
Study: NCT02258919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC) and best medical treatment
Description: Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
Study: NCT05285163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: palliative care educatiom
Description: The patients in the intervention group were presented palliative care training in addition to their usual care
Study: NCT03375307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study: NCT00453388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT04006717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra canal Cryotherapy
Description: Irrigation with cold saline 2-4 C
Study: NCT00453388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study: NCT02638064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgiflo injection
Description: Curettage of sinus cavity then injection of surgiflo material
Study: NCT03838848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, Q3W, intravenous injection (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningetinib
Description: Oral, QD
Study: NCT00501852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Handihaler inhaler
Study: NCT00638846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A toric
Description: silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric
Description: silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)